Jerald Radich, MD
Clinical Research Division
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Center
Dr. Jerald Radich is a medical oncologist who specializes in the molecular genetics of leukemia. He also directs Fred Hutch’s Molecular Oncology Lab, which provides high-quality molecular testing for clinical cancer researchers at Fred Hutch and around the world.
His research involves developing methods to improve the detection and treatment of chronic and acute myeloid leukemias, or CMLs and AMLs, and studying how specific genetic variants influence treatment responses and outcomes.
In this webinar, Dr. Radich shares the importance of MRD analysis in AML disease progression, prognosis, and therapy selection. He explains the challenges of traditional MRD testing methods and how next-generation sequencing (NGS) is rapidly emerging as a powerful technique for comprehensive and highly sensitive MRD detection.
Lastly, Dr. Radich discusses the latest research and shares his perspective on the future of MRD detection with NGS.
